• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection

tetano

Editor, Senior Moderator
PLoS Pathog. 2017 Apr 14;13(4):e1006326. doi: 10.1371/journal.ppat.1006326. [Epub ahead of print]
[h=1]RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection.[/h] Downey J[SUP]1[/SUP], Pernet E[SUP]1[/SUP], Coulombe F[SUP]1[/SUP], Allard B[SUP]1[/SUP], Meunier I[SUP]1[/SUP], Jaworska J[SUP]1[/SUP], Qureshi S[SUP]1[/SUP], Vinh DC[SUP]1[/SUP], Martin JG[SUP]1[/SUP], Joubert P[SUP]2[/SUP], Divangahi M[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The type I interferon pathway plays a critical role in both host defense and tolerance against viral infection and thus requires refined regulatory mechanisms. RIPK3-mediated necroptosis has been shown to be involved in anti-viral immunity. However, the exact role of RIPK3 in immunity to Influenza A Virus (IAV) is poorly understood. In line with others, we, herein, show that Ripk3-/- mice are highly susceptible to IAV infection, exhibiting elevated pulmonary viral load and heightened morbidity and mortality. Unexpectedly, this susceptibility was linked to an inability of RIKP3-deficient macrophages (Mφ) to produce type I IFN in the lungs of infected mice. In Mφ infected with IAV in vitro, we found that RIPK3 regulates type I IFN both transcriptionally, by interacting with MAVS and limiting RIPK1 interaction with MAVS, and post-transcriptionally, by activating protein kinase R (PKR)-a critical regulator of IFN-β mRNA stability. Collectively, our findings indicate a novel role for RIPK3 in regulating Mφ-mediated type I IFN anti-viral immunity, independent of its conventional role in necroptosis.


PMID: 28410401 DOI: 10.1371/journal.ppat.1006326
 
Back
Top Bottom